
Caroline Palm-Apergi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8251743/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Protein Delivery by PTDs/CPPs. Methods in Molecular Biology, 2022, 2383, 257-264.	0.4	4
2	RNAi prodrugs decrease elevated mRNA levels of Poloâ€like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients. FASEB Journal, 2021, 35, e21476.	0.2	6
3	Thermal proteome profiling identifies PIP4K2A and ZADH2 as offâ€ŧargets of Poloâ€ŀike kinase 1 inhibitor volasertib. FASEB Journal, 2021, 35, e21741.	0.2	5
4	Small-molecule inhibitors for targeting polo-like kinase 1. Future Medicinal Chemistry, 2020, 12, 1457-1460.	1.1	2
5	Targeting Plk1 with siRNNs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients. Scientific Reports, 2020, 10, 2688.	1.6	11
6	Polo-like kinases and acute leukemia. Oncogene, 2019, 38, 1-16.	2.6	54
7	Designing siRNA and Evaluating Its Effect on RNA Targets Using qPCR and Western Blot. Methods in Molecular Biology, 2019, 2036, 53-72.	0.4	Ο
8	STAT3 is activated in multicellular spheroids of colon carcinoma cells and mediates expression of IRF9 and interferon stimulated genes. Scientific Reports, 2019, 9, 536.	1.6	9
9	RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients. Journal of Controlled Release, 2017, 261, 199-206.	4.8	17
10	Identification of novel small molecules that inhibit STAT3-dependent transcription and function. PLoS ONE, 2017, 12, e0178844.	1.1	17